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Evans syndrome in a pediatric liver transplant 
recipient with an autoantibody with apparent 
specificity for the KEL4 (Kpb) antigen
S.A. Koepsell, K. Burright-Hittner, and J.D. Landmark
Although most warm red blood cell (RBC) autoantibodies react 
broadly with panel cells in addition to the patient’s own RBCs, 
occasionally an autoantibody with specificity for a specific blood 
group antigen is encountered. Rare cases of warm autoantibodies 
with specificity for the Kpb antigen of the Kell blood group system 
have been described. We report a pediatric transplant recipient 
with anemia, immune-mediated hemolysis, thrombocytopenia, 
and a warm autoantibody with apparent anti-Kpb specificity. The 
patient’s autoimmune anemia and thrombocytopenia responded 
well to discontinuing the immunosuppressant tacrolimus, trans-
fusions with Kp(b–) RBCs, and intravenous immunoglobulin 
therapy, with disappearance of the pathologic antibody. During 
the autoimmune hemolysis, the patient’s RBCs did not react with 
antisera specific for Kpb. However, repeat testing of the patient’s 
RBCs with Kpb-specific antisera 15 months after the resolution of 
hemolysis showed reactivity, indicating that the RBC autoantibody 
was associated with a transient disappearance of the Kpb antigen. 
Immunohematology 2014;30:14–17.
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Warm autoantibodies are a broad category of immuno-
globulins that react with a patient’s own antigens optimally 
at 37°C. Their incidence is 1 in 50,000 to 80,000 patients.1 
Depending on clinical background, antibody specificity, 
antibody titer, immunoglobulin subclass, and other less 
defined variables, warm autoantibodies may be associated 
with an autoimmune hemolytic anemia (AIHA), especially if 
the direct antiglobulin test (DAT) is reactive for complement 
C3 in addition to immunoglobulin G (IgG).2
Although most warm autoantibodies display broad 
specificity, many examples have been reported of autoanti-
bodies with well-defined specificity, most commonly against 
antigens of the Rh and LW blood group systems.2,3 Although 
extremely rare, warm autoantibodies with anti-Kpb specificity 
have been reported.4–8 The most common of three antithetical 
antigens, Kpb (KEL4) is an antigen that is formed by the 
presence of an arginine at amino acid 281 of the Kell protein. 
Substitution of the arginine with tryptophan generates the 
Kpa antigen (present in 2.3% of whites), and substitution with 
glutamine generates the Kpc antigen, which is extremely rare.
In transplant recipients, the presence of an apparent 
autoantibody also raises the possibility that the pathologic 
antibody may not be a true autoantibody, but rather an 
alloantibody arising from lymphocytes of donor origin from 
the transplanted organ, a term called passenger lymphocyte 
syndrome (PLS).9 PLS often occurs within weeks of transplant 
and usually involves an antibody with defined specificity 
that is mismatched between the donor and the recipient. An 
additional consideration in transplant recipients who develop 
red blood cell (RBC) autoantibodies are immunosuppressant 
drugs, which may have unknown consequences on the ability 
of the immune system to regulate autoimmunity. Tacrolimus 
in particular is an immunosuppressant that has been reported 
to be associated with AIHA by an unknown mechanism in 
transplant recipients based on the observation that pathologic 
warm autoantibodies seem to resolve after discontinuation of 
the drug.10,11
We report here an unusual case of a liver transplant 
recipient who developed an AIHA and thrombocytopenia 
(Evans syndrome), with the autoantibody having apparent 
specificity for the Kpb antigen. The patient responded well to 
discontinuing her tacrolimus, transfusion of Kp(b–) RBCs, 
and intravenous immunoglobulin (IVIG) therapy, with the 
autoantibody becoming undetectable.
Case Report
The patient was a 2-year-old group O, D+ girl who 
received a cadaveric liver transplant at 7 months of age to 
treat congenital biliary atresia. Her postoperative course 
was significant for pneumonia, one episode of liver rejection, 
and ascites. Eight months after transplantation, the patient 
presented with difficulty breathing and fatigue. She was found 
to have a hemoglobin (Hb) concentration of 6.2 g/dL, down 
from 10.0 g/dL 2 weeks earlier. Her immunosuppression 
regimen was tacrolimus at 1.5 mg, twice daily. Pretransfusion 
testing at this time showed a negative antibody screen. 
The patient subsequently received 15 mL/kg of irradiated, 
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leukocyte-reduced, cytomegalovirus (CMV)-negative group O, 
D+ RBCs. Her Hb level increased to 9.4 g/dL after transfusion. 
Infectious disease testing at this time showed positive nucleic 
acid amplification results for Epstein-Barr virus (28,000 
copies/mL), human herpes virus 6, and rhinovirus. The 
patient recovered and was discharged 1 day after admission.
Five days after being discharged, the patient was referred 
to a pediatric hematologist after being seen in the clinic with 
an Hb concentration of 8.4 g/dL. Eleven days after discharge, 
the patient had an Hb level of 6.8 g/dL, an absolute reticulocyte 
count of 70,000/µL, and a platelet count of 45,000/µL, and her 
RBCs were negative in the DAT with polyspecific antiglobulin 
reagent. Nucleic acid amplification testing for parvovirus B19 
was negative. Physical examination was significant for an 
enlarged spleen. The patient again had a negative antibody 
screen and received 90 mL of irradiated, leukocyte-reduced, 
CMV-negative group O, D+ RBCs. A bone marrow biopsy was 
performed, which showed trilineage hematopoiesis with a 
decreased number of megakaryocytes.
Ten days after the bone marrow biopsy and transfusion, 
the patient’s Hb concentration was 8.7 g/dL and her platelet 
count was 15,000/µL. The patient then received two units of 
single-donor, leukocyte-reduced, irradiated, CMV-negative 
platelets, and her platelet count increased to 228,000/µL. 
Again, the patient’s Hb level continued to decline to 7.8 g/dL, 
and the patient was given RBCs, which brought her Hb 
concentration up to 10.8 g/dL. On the following day, the patient 
received another unit of platelets. Six days after the last unit 
of RBCs and 5 days after the last unit of platelets, the patient 
was again anemic with an Hb concentration of 7.4 g/dL. An 
antibody screen performed at this time was positive, with all 
three cells in the panel reacting with 1+ reactivity at the anti-
human globulin phase. A polyspecific DAT was 2+ positive, 
with similar reactivity observed with anti-IgG monospecific 
reagent. A peripheral blood smear showed RBCs with crenated 
and teardrop morphology.
The patient’s specimen was forwarded to the American 
Red Cross regional reference laboratory, where the DAT 
was confirmed to be positive (1+) with anti-IgG reagent, but 
negative with anti-complement reagent. An antibody screen 
including an auto-control was reactive with all cells at room 
temperature, showing 1+ to 2+ reactivity. As part of the protocol 
for initial testing of a suspected autoantibody, the sample was 
prewarmed, which did not resolve the reactivity. An eluate 
was prepared and tested, which subsequently reacted with all 
cells tested. Its reactivity with the ficin-treated reagent cells 
increased to 4+ at 37°C, and no reactivity was observed with 
dithiothreitol-treated reagent cells. The patient’s cells were 
treated with an ethylenediaminetetraacetic acid–glycine acid 
(EGA) solution and were DAT-negative. The patient’s plasma 
and eluate both reacted with the EGA-treated cells, indicating 
a true autoantibody.
The patient’s plasma was then tested against a panel 
of antigen-negative rare RBCs that included cells negative 
for the Rh, Joa, Hy, PP1Pk, and Kpb antigens in low-ionic-
strength saline (LISS) at 37°C. Reactivity was observed with 
all the cells tested, with the exception of the Kp(b–) cells. The 
patient’s plasma was nonreactive with four different reagent 
cells that were Kp(a+b–). Antisera with Kpb specificity did 
not agglutinate the patient’s RBCs. The American Red Cross 
reference laboratory also performed molecular genotyping 
of the patient’s peripheral blood leukocytes using HEA 
Beadchip™. This technology identified that patient as 
demonstrating the Kpb genotype in her peripheral blood 
leukocyte DNA, despite the nonreactivity with the Kpb-specific 
antisera.
During this time, the patient underwent both a lower and 
upper endoscopy, which ruled out significant gastrointestinal 
bleeding or pathology. Her immunosuppressant regimen was 
changed from tacrolimus to cyclosporin, 50 mg twice per day. 
A lactate dehydrogenase (LDH) level at this time was elevated 
at 392 units (normal, 140–304 units). Sixteen days after the 
first positive DAT, the patient was provided with Kp(b–) and 
K– RBCs, which were nonreactive with the patient’s serum 
without enhancement but did have weak reactivity with 
LISS and anti-IgG reagent. Her Hb concentration increased 
from 6.0 g/dL to 10.8 g/dL. Four days after her Kp(b–) RBC 
transfusion, the patient was started on IVIG, 12 g per day for 
4 days. During the third day of IVIG treatment, an antibody 
screen was negative and a subsequent polyspecific DAT was 
also negative. All antibody screens and DATs performed since 
this episode have been negative. Fifteen months later, the 
patient’s RBCs were reactive with Kpb antisera. The patient’s 
clinical course is summarized in Table 1.
Discussion
We report a liver transplant recipient who developed 
AIHA. The etiology of the autoantibody is unknown, but may 
have been associated with her antecedent viral illnesses that 
occurred near the time of her first bout of anemia and before 
her first positive antibody screen. Although the possibility 
exists that the anti-Kpb was actually an alloantibody as a 
result of PLS, this is unlikely, as the Kpb antigen is highly 
prevalent in the population. In addition, the timing of the 
patient’s hemolysis occurred 8 months after transplantation, 
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whereas PLS usually occurs within a couple of weeks after 
transplantation. Further, genetic analysis performed on the 
formalin-fixed paraffin-embedded liver biopsy obtained from 
the transplanted liver while the organ was being prepared for 
transplant was homozygous for the Kpb allele, essentially ruling 
out the possibility that donor lymphocytes could recognize the 
Kpb antigen as foreign.12
Serologic workup found a warm autoantibody in her 
plasma that had specificity for the Kpb antigen. However, 
antisera specific for the Kpb antigen did not agglutinate the 
patient’s RBCs at the time of the anemia. To classify the 
pathologic antibody as an autoantibody or alloantibody, 
molecular genotyping was performed that identified the patient 
as being homozygous for the gene encoding Kpb. The patient 
was successfully treated with discontinuing her tacrolimus, 
transfusion of Kp(b–) blood, and administration of IVIG, with 
complete resolution of the pathologic antibody.
Table 1 shows that from mid-November 2009 through 
mid-January 2010, the child developed repeatedly low 
hemoglobin levels requiring transfusions. Clinically, there 
was no evidence of bleeding. During this period, the child’s 
hemoglobin decreased at an initial rate of 0.24 g/dL/day, which 
increased to over 1 g/dL/day before starting IVIG therapy. 
Although the patient did not have elevated bilirubin during 
this period, she was clinically diagnosed as having AIHA 
because of the lack of clinical evidence of bleeding, the increased 
LDH level, and the increased level of circulating reticulocytes 
along with the warm autoantibody that was identified. The 
patient also had persistent thrombocytopenia during this 
time, which may indicate that this case of AIHA may actually 
be part of an Evans syndrome. Interestingly, a case of Evans 
syndrome in a pediatric liver transplant recipient has been 
reported in which the cytopenias were successfully treated by 
switching the patient from tacrolimus to cyclosporine.13
Previous case reports have identified that patients with 
Kpb-specific autoantibodies have a depression in the Kell 
antigens on their RBCs that rebounds after resolution of the 
autoantibody.8,14 A similar observation was made in this case, 
as the patient’s RBCs failed to agglutinate with Kpb-specific 
antisera during the peak of her AIHA. Appropriate controls 
showed that the Kpb-specific antisera agglutinated reagent 
cells. Fifteen months after the resolution of the patient’s 
anemia, her cells did agglutinate with Kpb-specific antisera. 
Thus, the apparent negative reaction with anti-Kpb may be a 
result of a similar mechanism of Kell antigen downregulation 
in response to an autoantibody as previously reported,15 or 
that our patient simply had a serologically “blocked” antigen 
owing to her specific autoantibody. The process of how an 
Table 1. Clinical and laboratory data obtained from a pediatric liver transplant recipient who developed autoimmune hemolytic anemia*
Hemoglobin Platelets
Date Before transfusion After transfusion Before transfusion After transfusion DAT Ab Screen Transfusion
10/29/2009 10 288
11/13/2009 6.2 9.4 212 Neg 135 mL PRBC
11/25/2009 6.8 8.7 45 Neg Neg 90 mL PRBC
12/7/2009 15 133 50 mL A+ platelets
12/8/2009 54 228 45 mL A+ platelets
12/15/2009 7.8 64 Neg
12/16/5009 10.8 64 135 mL PRBC
12/17/2009 29 92 51 mL A+ platelets
12/22/2009 7.4 54 Pos Pos
12/23/2009 Tacrolimus discontinued
1/7/2010 6.0 7.8 121 100 mL Kp(b–) PRBC
1/8/2010 7.8 10.8 100 mL Kp(b–) PRBC
1/12/2010 Initiation of IVIG therapy
1/14/2010 9.0 179 Neg
1/22/2010 9.9 231 Neg
3/14/2010 12.6 13.3 343 Neg 100 mL PRBC
3/24/2010 11.9 12.3 278 Neg
4/6/2010 10.9 364 Neg
DAT = direct antiglobulin test; Ab = antibody; Neg = negative; PRBC = packed red blood cells; Pos = positive; IVIG = intravenous immunoglobulin G.
* Timeline of the patient’s hemoglobin (g/dL), platelet count (cells/μL), DAT, Ab screen, and quantity and type of transfused product. All cellular blood products 
were irradiated.
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autoantibody to the Kpb antigen results in downregulation of 
the antigen is not known.
A common theme among the handful of case reports 
describing warm autoantibodies with Kpb specificity is resolu-
tion of the autoantibody with either time or treatment.8,14,16 
Our case report affirms this trend, with our patient’s Kpb 
autoantibody completely disappearing 23 days after first 
being discovered. The patient’s hemoglobin responded well 
to Kp(b–) blood transfusions. Discontinuing tacrolimus and 
administering IVIG may have played a role as well, as the 
antibody became undetectable shortly after IVIG therapy was 
administered. In summary, we report a pediatric solid-organ 
transplant recipient who developed a warm autoantibody with 
apparent Kpb specificity that responded well to treatment and 
was associated with transient depression of the Kpb antigen on 
the patient’s RBC surface.
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